Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06725758 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours
A Phase 1 study, sponsored by Orion Corporation, Orion Pharma.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 315
- Enrollment target
NCT06725758: Recruiting Phase 1 study, sponsored by Orion Corporation, Orion Pharma.
NCT06725758 is a Phase 1 study that is actively recruiting participants, run by Orion Corporation, Orion Pharma. The registered enrollment target is 315 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (425% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06725758, a Phase 1 study, is actively recruiting participants, sponsored by Orion Corporation, Orion Pharma.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 315 participants
- Enrollment target
Study Summary
Multi-site, open-label, first-in-human study with 2 parts (dose escalation and dose expansion) in subjects with selected advanced solid tumours
Primary Outcome
A TEAE is defined as any event arising or worsening after the start of treatment administration until 28 days after the last treatment intake.
Interventions
- DRUG ODM-212
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 315 participants |
| Start Date | 2023-10-26 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 1 |
What NCT06725758 shows while recruiting
NCT06725758 is an interventional study that assigns participants to a tested intervention. The registered 315 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (425% higher).
The record links to 0 conditions, and to 1 intervention - of which ODM-212 is the first listed.
NCT06725758 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06725758 about?
NCT06725758 is a clinical study titled "A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours". Multi-site, open-label, first-in-human study with 2 parts (dose escalation and dose expansion) in subjects with selected advanced solid tumours
What is the current status of trial NCT06725758?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 315 participants. The study started on 2023-10-26. Estimated completion is 2027-12-31.
What interventions are being tested in trial NCT06725758?
The interventions under investigation include: ODM-212 (DRUG).
Who is sponsoring clinical trial NCT06725758?
This trial is sponsored by Orion Corporation, Orion Pharma, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06725758's enrollment target sits among peer trials
315 117th of 2000 higher than 1,883 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04812366 · 315 participants · Phase 2
Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
- NCT05101460 · 315 participants
An All Comers Registry For Normothermic Ex Vivo Lung Perfusion (EVLP) as Assessment of Donor Lungs for Transplant
- NCT05897320 · 315 participants · Phase 3
A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
- NCT06439082 · 315 participants · Phase 3
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI